Trial Profile
Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Adenocarcinoma; Biliary cancer; Intestinal cancer
- Focus Therapeutic Use
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
- 30 Jan 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.